Early Proof Of Mechanism Findings Would Boost R&D Productivity, Exec Says
Establishing proof of a therapy's mechanism before proof of concept would enhance R&D productivity, Archemix CEO Errol De Souza, PhD, said April 16
You may also be interested in...
FDA's top priorities for drug development guidances are in the areas of oncology, diabetes and obesity
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials